Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissions for the patents.

Practitioner's Docket No. MBIO99-054CP1M

PATENT

Certificate of Transmission under 37 CFR 1.8

OFFICIAL

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on <u>27 March 2003.</u>

FAX RECEIVED

MAR 28 onna

1600 GROUP

Simonne Corrivéau Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify

Submitted herewith:

Transmittal Letter

Revocation of Prior Powers of Attorney and Appointment of

(2 pages)

New Power of Attorney

(2 pages)

Change of Attorney Docket No.

(1 page)

Total

(6 pages-including fax cover sheet)

TO/SB/97 (08-00)

TO/SB97 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kirst, Susan J., et al.

Application No.:

09/596,194

Group No.:

1634

Filed: For:

June 16, 2000 NOVEL

Examiner:

Janell E. Taylor

HAVING

DIAGNOSTIC,

GENES

ENCODING **PROTEINS** PREVENTIVE, THERAPEUTIC, AND OTHERS USES

Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

- Transmitted herewith for this application is/are:
 - This Transmittal Letter (2 pages);
 - Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney (2 b.
 - Change of Attorney Docket Number (I page). ¢.

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, 37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Address" Mailing Label No.

 \square transmitted by facsimile to the Patent and Trademark Office.

Date: March 27, 2003

TRANSMISSION

Simonne Corriveau

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page I of 2)

Application No. <u>09/596,194</u>

FEE DEFICIENCY

If any additional extension and/or fee is required, charge Account No. 501668.
 If any additional fee for claims is required, charge Account No. 501668.

March 26, 2003

MILLENNIUM PHARMACEUTICALS, INC.

Paul J. Paglierani

Registration No. 52,498

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-761-6865

Facsimile - 617-551-8820

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kirst, Susan J., et al

Application No.:

09/596,194

Group No.:

1634

Filed:

June 16, 2000

Examiner:

Janell E. Taylor

For:

NOVEL GENES ENCODING PROTEINS HAVING DIAGNOSTIC,

PREVENTIVE, THERAPEUTIC, AND OTHER USES

Commissioner for Patents Washington, D.C. 20231

REVOCATION OF PRIOR POWERS OF ATTORNEY AND APPOINTMENT OF NEW POWER OF ATTORNEY

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Assignment document filed with the United States Patent and Trademark Office on November 21, 2000, at Reel 011331, Frame 0197 hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10* I hereby certify that, on the date shown below, this correspondence is being: MAILING deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, 37 C.F.R. SECTION 1.8(a) 37 C.F.R. SECTION 1.10* with sufficient postage as first class mail. as "Express Mail Post Office to Address" Mailing Label No. **TRANSMISSION** transmitted by facsimile to the Patent and Trademark Office. \square Signature Date: March 27, 2003 Simonne Corriveau (type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439,

(Page 1 of 2)

Application No. 09/596,194

Scott A. Brown, Reg. No. 32,724; Ian R. Silverman, Reg. No. 37,443; Jean M. Silveri, Reg. No. 39,030; Allan N. Kutzenco, Reg. No. 38,945, Janice M. Klunder, Reg. No. 41,121; Theodore R. Allen, Rcg. No. 41,578; Kerri Pollard Schray, Reg. No. 47,066, Tracy M. Sioussat, Reg. No. 50,609; and Paul J. Paglierani, Reg. No. 52,498

all of Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts 02139, United States of America.

Please direct all future correspondence to:

Intellectual Property Group MILLENNIUM PHARMACEUTICALS, INC. 75 Sidney Street Cambridge, MA 02139

MILLENNIUM PHARMACEUTICALS, INC. and direct all telephone calls to Paul J. Paglierani at (617) 761-6865.

By:

Typed Name: Jean M. Silveri

Title: Associate General Counsel

Dated: March 27, 2003

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kirst, Susan J., et al

GENES

Application No.:

09/596,194

Group No.:

1634

Filed: For:

June 16, 2000 NOVEL

Examiner:

Janell E. Taylor HAVING

DIAGNOSTIC,

ENCODING PROTEINS PREVENTIVE, THERAPEUTIC, AND OTHER USES

Commissioner for Patents Washington, D.C. 20231

CHANGE OF ATTORNEY DOCKET NUMBER

Dear Sir:

Please note that the Attorney Docket Number has been changed from

10147-25 (MBIO99-054) to MBIO99-054CP1M. Please reference MBIO99-054CP1M on all future correspondence.

Respectfully submitted,

March 27, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By

Paul J. Paglierant

Registration No. 52,498

75 Sidney Street

Cambridge, MA 02139 Telephone - 617-761-6865

Facsimile - 617-551-8820

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington,

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail,

as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION transmitted by facsimile to the Patent and Trademark Office. \square

Signature

Simonne Corriveau

Date: March 27, 2003

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing, 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 1)